Argenx SE is a biopharmaceutical company based in Belgium, focusing on the development and commercialization of innovative therapies for the treatment of autoimmune diseases and malignant tumors. The company specializes in the development of monoclonal antibodies and utilizes its technology platform for the discovery and development of new drug candidates. Argenx focuses on therapeutic areas such as immunology, hematology, and oncology, aiming to provide potential treatments for patients with severe diseases who have limited therapeutic options available. The company also collaborates with pharmaceutical partners on the development and commercialization of its products. Argenx SE could be suitable for investors seeking opportunities in the biotechnology and pharmaceutical industries, with an emphasis on innovative therapies for the treatment of serious diseases.